HopeStage
Back to all studies
CompletedNCT02511886

Arbaclofen Placarbil Dose and Tolerability for Alcohol Use

About this title

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Read the official source — NCT02511886
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Oakland ParkSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 2015
Recruitment status
Completed
Enrollment listed in the registry
18
Sponsor
Indivior Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT02511886
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Oakland Park

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Indivior Inc.

Did this study involve medication?

Yes. The study involved medication, including Arbaclofen Placarbil and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies